Phio Pharmaceuticals (PHIO) stock underwent a massive rally on Monday after the biotechnology company announced results from a Phase 1b trial of its proprietary INTASYL gene-silencing technology. This clinical trial focused on the use of INTASYL to eliminate cancer.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Today’s news included the positive treatment of three patients with cutaneous squamous cell carcinoma. The first patient in the study experienced a 100% elimination of their cancer, the second experienced a 90% elimination, and the final patient experienced a 50% elimination. Additionally, six patients with cutaneous squamous cell carcinoma and one patient with metastatic melanoma had a pathologic non-response.
Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals, said, “The encouraging outcomes of intratumoral PH-762 in patients who have received treatment thus far is a significant step in clinical development and highlights the promise of a viable non-surgical alternative treatment for cutaneous carcinomas.”
Phio Pharmaceuticals Stock Movement Today
Phio Pharmaceuticals stock was up 76.59% in pre-market trading on Monday, following a slight dip on Friday. The stock has rallied 13.89% year-to-date but was down 36.14% over the past 12 months.
With today’s clinical trial news came heavy trading of PHIO stock. As of this writing, more than 78 million shares have changed hands, compared to a three-month daily average of about 73,000 units.
Is Phio Pharmaceuticals Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Phio Pharmaceuticals is Moderate Buy, based on a single Buy rating over the past three months. With that comes an average PHIO stock price target of $14, representing a potential 582.93% upside for the shares.
